Yokukansan inhibits neuronal death during ER stress by regulating the unfolded protein response

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Hiratsuka, Toru ^a   Matsuzaki, Shinsuke ^a,b   Miyata, Shingo ^a   Kinoshita, Mitsuhiro ^c   Kakehi, Kazuaki ^c   Nishida, Shinji ^a   Katayama, Taiichi ^b   Tohyama, Masaya ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 4; CCAAT ENHANCER BINDING PROTEIN; FERULIC ACID; GLUCOSE REGULATED PROTEIN 78; HERBACEOUS AGENT; NEUROPROTECTIVE AGENT; PRESENILIN 1; TJ 54; UNCLASSIFIED DRUG; YOKUKANSAN; YI GAN SAN; YI-GAN SAN;

ALZHEIMER DISEASE; ANGELICA; ANIMAL CELL; ARTICLE; ATRACTYLODES; BUPLEURUM; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CNIDIUM; CONTROLLED STUDY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; GLYCYRRHIZA; HUMAN; HUMAN CELL; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PORIA; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; UNCARIA; UPREGULATION; WESTERN BLOTTING; ANIMAL; APOPTOSIS; DRUG EFFECT; ENDOPLASMIC RETICULUM; METABOLISM; MUTATION; NERVE CELL; PROTEIN DENATURATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DRUGS, CHINESE HERBAL; ENDOPLASMIC RETICULUM; MICE; MUTATION; NEURONS; PROTEIN DENATURATION; SIGNAL TRANSDUCTION;

EID: 78149429507     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013280     Document Type: Article

References (49)

1. Mizukami K, Asada T, Kinoshita T, Tanaka K, Sonohara K, et al. (2009) A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol 12(2): 191-199.
2. Monji A, Takita M, Samejima T, Takaishi T, Hashimoto K, et al. (2009) Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 33(2): 308-311.
3. Shinno H, Kamei M, Nakamura Y, Inami Y, Horiguchi J (2008) Successful treatment with Yi-Gan San for rapid eye movement sleep behavior disorder. Prog Neuropsychopharmacol Biol Psychiatry 32(7): 1749-1751.
4. He LM, Chen LY, Lou XL, Qu AL, Zhou Z, et al. (2002) Evaluation of betaamyloid peptide 25-35 on calcium homeostasis in cultured rat dorsal root ganglion neurons. Brain Res 939(1-2): 65-75.
5. Pereira C, Ferreiro E, Cardoso SM, de Oliveira CR (2004) Cell degeneration induced by amyloid-beta peptides: implications for Alzheimer's disease. J Mol Neurosci 23(1-2): 97-104.
6. Yu MS, Suen KC, Kwok NS, So KF, Hugon J, et al. (2006) Beta-amyloid peptides induces neuronal apoptosis via a mechanism independent of unfolded protein responses. Apoptosis 11(5): 687-700.
7. Katayama T, Imaizumi K, Sato N, Miyoshi K, Kudo T, et al. (1999) Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol 1(8): 479-485.
8. Katayama T, Imaizumi K, Honda A, Yoneda T, Kudo T, et al. (2001) Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. J Biol Chem 276(46): 43446-43454.
9. Sato N, Hori O, Yamaguchi A, Lambert JC, Chartier-Harlin MC, et al. (1999) A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue. J Neurochem 72(6): 2498-2505.
10. Sato N, Imaizumi K, Manabe T, Taniguchi M, Hitomi J, et al. (2001) Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. J Biol Chem 276(3): 2108-2114.
11. Matsuzaki S, Manabe T, Katayama T, Nishikawa A, Yanagita T, et al. (2004) Metals accelerate production of the aberrant splicing isoform of the presenilin-2. J Neurochem 88(6): 1345-51.
12. Manabe T, Katayama T, Sato N, Gomi F, Hitomi J, et al. (2003) Induced HMGA1a expression causes aberrant splicing of Presenilin-2 pre-mRNA in sporadic Alzheimer's disease. Cell Death Differ 10(6): 698-708.
13. Sidrauski C, Chapman R, Walter P (1998) The unfolded protein response: an intracellular signaling pathway with many surprising features. Trends Cell Biol 8: 245-249.
14. Tirasophon W, Welihinda AA, Kaufman RJ (1998) A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. Genes Dev 12: 1812-1824.
15. Kozutsumi Y, Segal M, Normington K, Gething MJ, Sambrook JF (1988) The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature 332: 462-464.
16. Oyadomari S, Araki E, Mori M (2002) Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis 7(4): 335-45.
17. Oyadomari S, Mori M (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11(4): 381-9.
18. Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, et al. (2004) Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J Cell Biol 165(3): 347-356.
19. Yukioka F, Matsuzaki S, Kawamoto K, Koyama Y, Hitomi J, et al. (2008) Presenilin-1 mutation activates the signaling pathway of caspase-4 in endoplasmic reticulum stress-induced apoptosis. Neurochem Int 52(4-5): 683-687.
20. Srinivasan M, Sudheer AR, Menon VP (2007) Ferulic Acid: therapeutic potential through its antioxidant property, J Clin Biochem Nutr 40: 92-100.
21. Mukhopadhyay A, Basu, Ghatak N, Gujral PK (1982) Anti-inflammatory and irritant activities of curcumin analogues in rats, Agents Actions 12: 508-515.
22. Kawabata K, Yamamoto T, Hara A, Shimizu M, Yamada Y, et al. (2000) Modifying effects of ferulic acid on azoxymethane-induced colon carcinogenesis in F344 rats, Cancer Lett 157: 15-21.
23. Balasubashini MS, Rukkumani R, Viswanathan P, Menon VP (2004) Ferulic acid alleviates lipid peroxidation in diabetic rats, Phytother Res 18: 310-314.
24. Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA (2005) Ferulic acid ethyl ester protects neurons against amyloid beta-peptide(1- 42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity, J Neurochem 92: 749-758.
25. Yogeeta SK, Hanumantra RB, Gnanapragasam A, Senthilkumar S, Subhashini R et al (2006) Attenuation of abnormalities in the lipid metabolism during experimental myocardial infarction induced by isoproterenol in rats: beneficial effect of ferulic acid and ascorbic acid, Basic Clin Pharmacol Toxicol 98: 467-472.
26. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, et al. (2001) Protection against betaamyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 133(1): 89-96.
27. Picone P, Bondi ML, Montana G, Bruno A, Pitarresi G, et al. (2009) Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radic Res 43(11): 1133-45.
28. Wang X, Wang B, Fan Z, Shi X, Ke ZJ, et al. (2006) Thiamine deficiency induces endoplasmic reticulum stress in neurons. Neuroscience 144(3): 1045-56.
29. Ikarashi Y, Iizuka S, Imamura S, Yamaguchi T, Sekiguchi K, et al. (2009) Effects of yokukansan, a traditional Japanese medicine, on memory disturbance and behavioral and psychological symptoms of dementia in thiamine-deficient rats. Biol Pharm Bull 32(10): 1701-9.
30. Iizuka S, Kawakami Z, Imamura S, Yamaguchi T, Sekiguchi K, et al. (2010) Electron-microscopic examination of effects of yokukansan, a traditional Japanese medicine, on degeneration of cerebral cells in thiamine-deficient rats. Neuropathology, In press.
31. Tateno M, Ukai W, Ono T, Saito S, Hashimoto E, et al. (2008) Neuroprotective effects of Yi-Gan San against beta amyloid-induced cytotoxicity on rat cortical neurons. Prog Neuropsychopharmacol Biol Psychiatry 32(7): 1704-1707.
32. Sekiguchi K, Yamaguchi T, Tabuchi M, Ikarashi Y, Kase Y (2009) Effects of yokukansan, a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid beta protein into mice. Phytother Res 23(8): 1175-81.
33. Hayashi H, Tohda M, Watanabe H, Murakami Y, Matsumoto K (2005) The effects of Choto-san on the mRNA expression of Alzheimer's disease related factors in the permanent ischemic rat brain. Biol Pharm Bull 28(4): 744-746.
34. Pierrot N, Ghisdal P, Caumont AS, Octave JN (2004) Intraneuronal amyloidbeta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J Neurochem 88: 1140-1150.
35. Sun XD, Mo ZL, Taylor BM, Epps DE (2003) A slowly formed transient conformer of Abeta(1-40) is toxic to inward channels of dissociated hippocampal and cortical neurons of rats. Neurobiol Dis 14: 567-578.
36. Chafekar SM, Hoozemans JJ, Zwart R, Baas F, Scheper W (2007) Abeta 1-42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner. Antioxid Redox Signal 9: 2245-2254.
37. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, et al. (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148(5): 379-397.
38. Getsios D, Migliaccio-Walle K, Caro JJ (2007) NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? Pharmacoeconomics 25(12): 997-1006.
39. Seltzer B (2007) Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified? Drugs Aging 24(11): 881-890.
40. McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev;2): CD003154.
41. Giacobini E, Becker RE (2007) One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? J Alzheimers Dis 12(1): 37-52.
42. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31: 175-193.
43. Arbel M, Solomon B (2007) A novel immunotherapy for Alzheimer's disease: antibodies against the beta-secretase cleavage site of APP. Curr Alzheimer Res 4(4): 437-445.
44. Solomon B (2007) Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther 9(1): 79-85.
45. Hutton M, McGowan E (2004) Clearing tau pathology with Abeta immunotherapy- reversible and irreversible stages revealed. Neuron 43(3): 293-294.
46. Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 15(2): 157-168.
47. Treiman M, Caspersen C, Christensen SB (1998) A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca 2 +-ATPases. Trends Pharmacol Sci 19: 131-135.
48. Jackson TR, Patterson SI, Thastrup O, Hanley MR (1988) A novel tumour promoter, thapsigargin, transiently increases cytoplasmic free Ca2+ without generation of inositol phosphates in NG115-401L neuronal cells. Biochem J 253: 81-86.
49. Lee AS (2001) The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 26: 504-510.